Validation of the French Version of the Primary Lateral Sclerosis Functioning Rating Scale (PLSFRS) (FRENPRILS)
Validation of the French Version of the PLSFRS Scale
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Philippe CORCIA, Pr
- Phone Number: +33 0247473724
- Email: philippe.corcia@univ-tours.fr
Study Locations
-
-
-
Brest, France, 29000
- University Hospital
-
Clermont-Ferrand, France, 63000
- University Hospital
-
Lille, France, 59000
- University Hospital
-
Limoges, France, 87000
- University Hospital
-
Lyon, France, 69000
- University Hospital
-
Nice, France, 05000
- University Hospital
-
Tours, France, 37044
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with primary lateral sclerosis (PLS)
- Age over 18 years
- Informed consent signed
- Patients cared in a French ALS centre
Exclusion Criteria:
- patients with no oral and written command of the French language
- Patients unable to answer a questionnaire
- Opposition to data processing
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with a primary lateral sclerosis
|
assessment of their functional status using the French version of the PLSFRS scale during a routine multidisciplinary assessment every 3-6 months for all patients with motor neurone disease, as recommended by the FILSLAN network
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
French version of the PLSFRS scale
Time Frame: inclusion and 6 months
|
10 items with a score from 0 to 6; 2 items with a score from 0 to 4 Maximal score is 68.
|
inclusion and 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change Global Impression (CGI) scale
Time Frame: 6 months
|
overall clinical impression of the change; score from 1 to 7
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Philippe CORCIA, PR, University Hospital, Tours
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DR240260-FRENPRILS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.